Araclon's Alzheimer's Vaccine Shows Clean Safety Profile in Phase II Analysis
While the trial was designed to test safety and not efficacy, patients treated with Araclon Biotech’s experimental ABvac40 vaccine saw a 38% drop in disease progression compared to placebo.
Source: biospace.com